LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Slides:

Advertisements

Similar presentations

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Advertisements

ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines

NICE –CG 181 Continuum of CVD Risk and its treatment

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

AIM HIGH Niacin plus Statin to prevent vascular events

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

What Do We Know About LDL-C?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

62-year-old Man With Unstable Angina

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Advances in Hypertriglyceridemia Treatment

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Préparation ESC Septembre

Ezetimibe/simvastatin

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Potential mechanisms whereby statins may reduce the risk of stroke

A Family Affair.

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Addressing Cardiovascular Events:

Updates on Dyslipidemia

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

LDL-c reductions below 1

PCSK9 Inhibitors and Real-World Evidence

Presentation transcript:

The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

LDL-C Goals

Impact of Intensive Statin Therapy on Major Vascular Events

ENHANCE: Ezetimibe Lowers LDL-C Levels but Not Progression of Atherosclerosis

IMPROVE-IT: Ezetimibe/Simvastatin Combination vs Simvastatin Monotherapy

Coronary Drug Project: Niacin Associated With Reduction in Mortality in Men

AIM-HIGH: Niacin Improves Lipids but Not CV Events

Incidence of Muscle Adverse Effects

Statins in Patients With Dementia

ARIC: Reduced CHD Incidence in Individuals With PCSK9 Loss-of-Function Mutations

Horus: Atherosclerosis in Ancient Egypt

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk (FOURIER)

ODYSSEY Outcomes: Phase 3 Post-ACS With SAR236553

REVEAL Trial

ACCELERATE Trial

Homozygous FH: Novel Treatments

FH

Thank you for participating in this activity

Abbreviations

Abbreviations (cont)

References

References (cont)

References (Cont)

References (Cont)